The Gene Knockout Cell Line Construction Service market encompasses outsourced services that generate genetically engineered cell lines with targeted gene deletions using CRISPR, TALEN, or ZFN technologies. These services are critical for drug discovery, functional genomics, and biomanufacturing, enabling rapid validation of therapeutic targets. The Gene Knockout Cell Line Construction Service market size was estimated at USD 0.68 billion in 2025, and the market forecast projects it to reach approximately USD 1.5 billion by 2033, reflecting a CAGR of about 11.5% over the forecast horizon. Growth is propelled by escalating demand for precision medicine, expanding adoption of CRISPR‑based research, and rising investment in biologics pipelines. Macro‑level drivers include supportive regulatory frameworks for genome editing, cost efficiencies from automation, and the surge in academic‑industry collaborations that accelerate target validation.